- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02540434
Trial of RiaSTAP Versus Cryoprecipitate to Lower Operative Transfusions (TOP-CLOT)
Trial of RiaSTAP Versus Cryoprecipitate to Lower Operative Transfusions (TOP-CLOT)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
All eligible subjects undergoing cardiac surgery requiring cardiopulmonary bypass (CPB) at New York Presbyterian Hospital-Weill Cornell Medical College will be invited to participate. Consenting subjects will be enrolled and treated according to the protocol. Study investigators anticipate that by consenting all eligible cardiovascular surgical subjects, investigators will not omit the results of subjects who may present with microvascular bleeding after CPB. It is well known that microvascular bleeding occurs more often in reoperations or complex, open cardiac procedures, such as coronary revascularization and valve repair/replacement, or aortic replacements under deep hypothermic circulatory arrest.
Enrolled subjects will receive intraoperative anesthetic, anticoagulation, laboratory testing, and hemodynamic management according to WCMC standards of practice. The need for blood products, including fibrinogen supplementation (CRYO/FIB), will be assessed using a point-of-care (ROTEM) based transfusion algorithm (Appendix A) to ensure consistency and accuracy of treatment. The cardiac anesthesiologists and surgeons are currently using the ROTEM algorithm for the treatment of bleeding during cardiovascular surgery with CPB as part of routine clinical practice at WCMC. The algorithm will have been in place for greater than 9 months prior to study initiation. Randomization will occur in the blood bank when study product (CRYO/FIB) is requested to treat intraoperative acquired hypofibrinogenemia (based on ROTEM tracings). Transfusion of the randomized study product (CRYO/FIB), however, will only occur when the surgeon declares the presence of microvascular bleeding. Surgeons will be blinded to the subject's ROTEM results and randomized study arm. Intraoperative anesthesiologists will not be blinded as the two products require different preparation and administration techniques and cannot be blinded easily.
Once the subject is randomized to their study intervention they will receive that product at all subsequent points during the procedure when fibrinogen replacement is required. If microvascular bleeding occurs and there is no indication by the ROTEM algorithm to administer CRYO/FIB, the subject will revert to standard of care treatment guided by ROTEM or traditional laboratory testing. The subject will not be randomized in the study. In the case of abnormal ROTEM parameters but no clinical evidence of microvascular bleeding as evaluated by the cardiac surgeon, the subject will continue to be monitored carefully for bleeding for the remainder of the procedure. If non-surgical bleeding is subsequently observed prior to chest closure and the consensus is that fibrinogen is needed based on ROTEM results (FIBTEM A10 less than or equal to 10 mm), the subject will be treated with their randomized study product according to the algorithm. Following completion of the procedure, postoperative coagulation management will be according to standard practice and guided by standard laboratory testing, when possible. Unless persistent bleeding is noted, all subjects will receive aspirin (300 mg per rectum) 6 hours postoperatively. Subjects with mechanical or mitral tissue valves will be anticoagulated with warfarin (no heparin bridge) starting on postoperative day two (POD#2). Any subjects experiencing significant arrhythmias (e.g. atrial fibrillation in the perioperative setting) will also be anticoagulated with warfarin. Pharmacologic deep vein thrombosis (DVT) prophylaxis will follow the usual standard of care. Subjects enrolled, randomized, and transfused study product will be observed until hospital discharge (total observation time). Research staff from the Department of Anesthesiology will collect outcomes data, including transfused blood products, laboratory results, evidence of perioperative thrombosis or infection, returns to the OR, length of stay, and mortality using case report forms reports and enter all collected data into a secure REDCap database.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10065
- Weill Cornell Medical College
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All subjects age 18 and older who have given written informed consent
- Undergoing cardiac surgery cardiopulmonary bypass (CBP) at Weill Cornell Medical Center
Exclusion Criteria:
Subjects on anticoagulation medications including:
- Clopidogrel, ticagrelor, prasugrel with platelet function analyzer-100 assay closure time (CT) prolonged greater than 15%
- Last doses of dabigatran, rivaroxaban, apixaban within 72 hours
- Warfarin with international normalized ratio (INR) greater than 1.5
- Positive pregnancy test, pregnancy or lactation
- Thrombocytopenia: platelet count less than 100,000 u/L
- Emergency procedures
- Proof or suspicion of a congenital or acquired coagulation disorder (e.g. von Willebrand Factor or via severe liver disease)
- Participation in another randomized clinical trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: RiaSTAP Arm
Subjects will be infused with RiaSTAP if the ROTEM FIBTEM A10 value is less than or equal to 10 mm and microvascular bleeding is present.
|
ROTEM delta will be used to identify intraoperative coagulation abnormalities.
A blood sample and reagents are placed into a small cup.
A pin suspended from a wire is immersed into the sample.
The pin rotates back and forth at a fixed angle.
The movement of the pin is optically monitored and converted into a real time measurement that is represented graphically.
Prior to clot formation, pin rotation is unhindered and is graphically represented as a straight line.
As the subject's blood sample starts to clot, strands of clot form between the pin and the cup wall, restricting the movement of the pin depending on the strength of the clot.
Graphically, this is represented as a symmetrical widening of the curve.
Other Names:
Subjects with hypofibrinogenemia who are randomized to the RiaSTAP arm will be transfused with concentrated fibrinogen
Other Names:
|
Active Comparator: Cryopreciptiate Arm
Subjects will be infused with cryoprecipitate if the ROTEM FIBTEM A10 value is less than or equal to 10 mm and microvascular bleeding is present.
|
ROTEM delta will be used to identify intraoperative coagulation abnormalities.
A blood sample and reagents are placed into a small cup.
A pin suspended from a wire is immersed into the sample.
The pin rotates back and forth at a fixed angle.
The movement of the pin is optically monitored and converted into a real time measurement that is represented graphically.
Prior to clot formation, pin rotation is unhindered and is graphically represented as a straight line.
As the subject's blood sample starts to clot, strands of clot form between the pin and the cup wall, restricting the movement of the pin depending on the strength of the clot.
Graphically, this is represented as a symmetrical widening of the curve.
Other Names:
Subjects with hypofibrinogenemia who are randomized to the Cryoprecipitate arm will be transfused with Cryoprecipitate
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intraoperative Blood Transfusion Total
Time Frame: Procedure length, the average for participants is approximately 6 hours
|
The combined number of allogeneic blood products (platelets + Fresh Frozen Plasma (FFP) + RBCs) administered to subjects intraoperatively after study intervention.
|
Procedure length, the average for participants is approximately 6 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
24-hour Blood Transfusion Total
Time Frame: 24 hours
|
Number of units of RBC, Platelets, cryoprecipitate, FFP, or other blood products administered to subjects receiving study product within the first 24 hours after procedure end
|
24 hours
|
Fibrinogen Repletion
Time Frame: Procedure length, the average for participants is approximately 6 hours
|
Fibrinogen repletion as measured by ROTEM FIBTEM >10mm after study product administration.
Trial terminated prior to the collection of this data due to feasibility issues preventing completion of recruitment
|
Procedure length, the average for participants is approximately 6 hours
|
Incidence of Zero Transfusions
Time Frame: 24 hours
|
Number of patients who receive no allogeneic blood transfusions following study product administration and first 24 hours after procedure end.
Trial terminated prior to the collection of this data due to feasibility issues preventing completion of recruitment
|
24 hours
|
Correction of Microvascular Bleeding
Time Frame: ~30 min intraoperatively
|
Difference in surgeon's assessment of microvascular bleeding from approximately 15 minutes before to approximately 15 minutes after administration of study medication.
Trial terminated prior to the collection of this data due to feasibility issues preventing completion of recruitment
|
~30 min intraoperatively
|
CTICU Length of Stay
Time Frame: Length of Hospital Stay, the average for participants is approximately 7 days
|
Number of days subject spends in cardiothoracic intensive care unit from procedure end to hospital discharge.
Trial terminated prior to the collection of this data due to feasibility issues preventing completion of recruitment
|
Length of Hospital Stay, the average for participants is approximately 7 days
|
Hospital Length of Stay
Time Frame: Length of Hospital Stay, the average for participants is approximately 7 days
|
Number of days subject spends in the hospital from procedure end to hospital discharge.
Trial terminated prior to the collection of this data due to feasibility issues preventing completion of recruitment.
|
Length of Hospital Stay, the average for participants is approximately 7 days
|
Thrombosis and Transfusion Reactions
Time Frame: Length of Hospital Stay, the average for participants is approximately 7 days
|
Incidence of intraoperative or postoperative (during hospital admission only) thrombosis (symptomatic only) and transfusion reactions from procedure to hospital discharge.
Trial terminated prior to the collection of this data due to feasibility issues preventing completion of recruitment.
|
Length of Hospital Stay, the average for participants is approximately 7 days
|
Infection and Respiratory Failure
Time Frame: Length of Hospital Stay, the average for participants is approximately 7 days
|
Incidence of any infection or respiratory failure from procedure end to hospital discharge.
Trial terminated prior to the collection of this data due to feasibility issues preventing completion of recruitment.
|
Length of Hospital Stay, the average for participants is approximately 7 days
|
Blood Loss
Time Frame: Length of Hospital Stay, the average for participants is approximately 7 days,
|
Quantity of intraoperative and postoperative blood loss as recorded in the anesthesia record and in chest tube outputs (blood drainage volume).
Trial terminated prior to the collection of this data due to feasibility issues preventing completion of recruitment.
|
Length of Hospital Stay, the average for participants is approximately 7 days,
|
Incidence of Re-exploration
Time Frame: Length of Hospital Stay, the average for participants is approximately 7 days
|
Incidence of subjects requiring a return to the OR for re-exploration.
Trial terminated prior to the collection of this data due to feasibility issues preventing completion of recruitment.
|
Length of Hospital Stay, the average for participants is approximately 7 days
|
Mortality Rate
Time Frame: Length of Hospital Stay, the average for participants is approximately 7 days
|
Rate of hospital death during initial hospital admission.
Trial terminated prior to the collection of this data due to feasibility issues preventing completion of recruitment
|
Length of Hospital Stay, the average for participants is approximately 7 days
|
Correlation of Laboratory and ROTEM Data
Time Frame: Procedure length, the average for participants is approximately 6 hours
|
Correlation of fibrinogen, von Willebrand Factor (vWF), and factor VIII levels measured in traditional lab with intraoperative ROTEM parameters.
Trial terminated prior to the collection of this data due to feasibility issues preventing completion of recruitment.
|
Procedure length, the average for participants is approximately 6 hours
|
Time to Product Administration
Time Frame: Procedure length, the average for participants is approximately 6 hours
|
Time from request to administration of study product.
Trial terminated prior to the collection of this data due to feasibility issues preventing completion of recruitment.
|
Procedure length, the average for participants is approximately 6 hours
|
Collaborators and Investigators
Investigators
- Principal Investigator: Nikolaos J Skubas, M.D., Weill Medical College of Cornell University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1408015402
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coagulopathy
-
University of ZurichCompleted
-
Emory UniversityWithdrawnTrauma-induced CoagulopathyUnited States
-
Mahidol UniversityCompleted
-
Goethe UniversityUnknownCoagulopathy During Cardiac SurgeryGermany, Austria
-
CSL BehringCompletedReversal of CoagulopathyUnited States, Belarus, Bulgaria, Lebanon, Romania, Russian Federation
-
Johns Hopkins UniversityTerminatedCirrhosis, Coagulopathy
-
The Hospital for Sick ChildrenSynapse B.V. Research Institute, University of MaastrichtUnknownPlatelet Function Tests | Thrombin Generation Tests | Perioperative CoagulopathyCanada
-
Monash UniversityNational Health and Medical Research Council, Australia; Health Research Council...CompletedPre-hospital Anti-fibrinolytics for Traumatic Coagulopathy and Haemorrhage (The PATCH Study) (PATCH)Wounds and Injuries | Acute CoagulopathyAustralia, New Zealand
-
Zdravotnicka Zachranna Sluzba Kralovehradeckeho...University Hospital Hradec KraloveUnknownWounds and Injuries | Trauma | Acute CoagulopathyCzechia
-
Petra Hartmann MD Ph.D.Not yet recruiting
Clinical Trials on ROTEM
-
Weill Medical College of Cornell UniversityTerminated
-
Tem Innovations GmbHUnknownBlood Coagulation DisordersUnited States, Austria, Switzerland
-
Samsung Medical CenterUnknownPostoperative Hemorrhage | Coagulation Defect; Bleeding | Other Functional Disturbances Following Cardiac SurgeryKorea, Republic of
-
Seoul National University Bundang HospitalCompletedPlacenta Accreta | Placenta Previa | Placenta Percreta | Placenta IncretaKorea, Republic of
-
Tampere University HospitalCSL BehringCompletedAneurysmatic Subarachnoid HaemorrhageFinland
-
AHEPA University HospitalCompletedCoagulation Disorder | Extracorporeal Circulation; Complications | Extracorporeal Circulation of Blood; ThrombocytopeniaGreece
-
University of UtahEnrolling by invitationPlacenta Accreta
-
Entegrion, Inc.UnknownHemostasis MonitoringUnited States
-
Johann Wolfgang Goethe University HospitalHemoSonics LLCTerminatedHemorrhage | BleedingGermany